BioBridgeX
Log inCompare quotes
Clinical

Phase 1 / Early Clinical Unit CROs

Free for buyersNeutral marketplace
Quick answer

A Phase 1 / Early Clinical Unit is a dedicated facility that runs first-in-human studies: single- and multiple-ascending-dose escalation, food-effect, and bioequivalence work, with beds, telemetry, and on-site PK sampling. You need it the moment your IND clears and you dose humans for the first time. On BioBridgeX, sponsors source and compare qualified GCP-compliant units and contract directly with their chosen supplier, free for buyers.

Phase 1 / Early Clinical Unit CROs on BioBridgeX

We are qualifying and publishing Phase 1 / Early Clinical Unit CROs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is a Phase 1 / Early Clinical Unit and when do you need it?

A Phase 1 / Early Clinical Unit is the place where your molecule meets a human being for the first time. It is a dedicated inpatient facility, beds, continuous telemetry, a resuscitation setup, an on-site pharmacy, and the staff and lab logistics to draw intensive PK samples on a tight schedule, so that a first-in-human study can be run safely under close observation. Most of these units enroll healthy volunteers, though some run patient cohorts for oncology and other indications where dosing a healthy person is not appropriate. The unit is purpose-built for the kind of dense, time-stamped data collection that early dosing demands, which is exactly what a general clinical site is not set up to do.

You need one the moment your IND goes into effect and you are cleared to dose humans. In practice the unit becomes part of the plan well before that, because the protocol design, the dose-escalation rules, the stopping criteria, and the PK sampling schedule all get built around what a given unit can actually execute. The studies that run here are recognizable: single-ascending-dose (SAD) and multiple-ascending-dose (MAD) escalation to map safety and tolerability and find the early dose range, food-effect studies to see whether a meal changes exposure, drug-drug interaction studies, QT/thorough-QT work, and bioequivalence or bioavailability studies for generics, reformulations, and bridging. A typical SAD/MAD program reads out within months once dosing starts, far faster than the later phases, because enrollment of a captive healthy-volunteer panel is the easy part.

Treat the unit as distinct from the broader clinical operations CRO that runs your multi-site Phase 2 and Phase 3. Early-phase work is its own discipline. It rewards a team that has dosed first-in-human compounds many times, knows how to handle an adverse event in real time, and can keep a sentinel-dosing escalation moving without drama. The medical cover, the speed of the on-site bioanalytical handoff, and the unit's experience with your modality matter more here than the size of the network.

What does a Phase 1 / Early Clinical Unit CRO actually do?

The unit owns the conduct of the early-phase study end to end, from volunteer recruitment and screening through dosing, monitoring, sample collection, and the clinical report. Its day job is execution under pressure: enrolling and medically screening a healthy-volunteer panel, admitting subjects to the ward, dosing on protocol (often with sentinel dosing where the first one or two subjects are dosed and watched before the rest of the cohort follows), running continuous safety monitoring, and pulling the intensive PK and PD samples on the exact timepoints the protocol specifies. The on-site pharmacy handles investigational product receipt, accountability, and blinding, and the unit's medical team makes the real-time calls that keep an escalation safe.

A good unit also carries the supporting machinery that makes the data usable. That means in-house or tightly partnered bioanalytical for fast turnaround on PK samples, ECG and telemetry capture for cardiac safety, an investigational pharmacy, and the GCP documentation trail that an FDA or EMA inspector will eventually read. Many units run their own ethics committee or IRB relationship and handle regulatory submissions for the study, and the stronger ones contribute to protocol design and dose-escalation strategy rather than just executing a protocol handed to them. For BE and bioavailability programs the unit also manages the crossover design, washout periods, and the comparator sourcing that those studies live or die on.

  • Healthy-volunteer recruitment, medical screening, and panel management, or patient cohorts where a healthy subject cannot be dosed
  • SAD and MAD dose-escalation conduct, including sentinel dosing and protocol-defined stopping rules
  • Continuous safety monitoring: telemetry, ECG, vitals, and on-site medical cover with resuscitation capability
  • Intensive PK and PD sampling on protocol timepoints, with fast bioanalytical turnaround
  • Food-effect, drug-drug interaction, QT/TQT, and bioequivalence or bioavailability study conduct
  • Investigational pharmacy: IP receipt, accountability, blinding, and dispensing
  • GCP documentation, trial master file, and inspection-ready records for FDA, EMA, and other regulators

How do you choose a Phase 1 / Early Clinical Unit CRO?

Start with fit to your specific study, not the size of the unit. A facility that runs flawless healthy-volunteer BE studies may be the wrong choice for a first-in-human oncology compound that needs patient dosing, and a unit that is strong in small molecules can be a beginner on a biologic or a cell therapy where infusion reactions and immunogenicity change the safety picture. Match the unit to your modality, your study type (FIH SAD/MAD versus BE versus a thorough-QT study), and the population you actually need to dose before you compare a single quote.

Past that, the questions that predict a clean early-phase study are practical and worth pinning down in writing. Use the checklist below as your first screen.

  • Quality and GxP status: confirm GCP compliance (ICH E6), a documented quality system, and a recent FDA or EMA inspection history with no unresolved findings. Ask to see the inspection record, do not take it on faith.
  • Capacity and lead time: ward beds, current booking queue, and a realistic start date. A great unit booked solid for months can be slower than a good unit with an open slot, so get the milestone timeline (screening, first dose, last subject, draft report) in writing.
  • Modality and indication fit: ask whether they have dosed your modality first-in-human before, and for oncology or other patient studies, whether they can run patient cohorts rather than only healthy volunteers.
  • Region and regulatory track record: confirm the unit's history with the regulator you plan to file with (FDA, EMA, PMDA, NMPA), since a clean inspection record where you intend to submit is what makes the data hold up.
  • Data quality and bioanalytical turnaround: PK sample handling, bioanalytical method readiness, CDISC-conformant data capture, and how fast samples become usable PK results, because slow bioanalytical can stall a dose-escalation decision.
  • IP and confidentiality: clear CDA terms, who handles the data, and how subject and study information is protected, especially for an undisclosed early asset.

Frequently asked questions

What is the difference between a Phase 1 unit and a general clinical operations CRO?
A Phase 1 / Early Clinical Unit is a dedicated inpatient facility built for first-in-human dosing: beds, telemetry, on-site medical cover, an investigational pharmacy, and intensive PK sampling on tight timepoints. A clinical operations CRO runs the broader multi-site Phase 2 and Phase 3 machinery, site selection, monitoring, project management, across many outpatient sites. Early-phase work is a separate discipline that rewards real first-in-human experience and fast safety decision-making, so sponsors often source the unit separately from the CRO that runs later phases.
What studies run at an Early Clinical Unit?
The core work is single-ascending-dose (SAD) and multiple-ascending-dose (MAD) escalation to map safety, tolerability, and the early dose range in first-in-human. Units also run food-effect studies, drug-drug interaction studies, QT and thorough-QT studies for cardiac safety, and bioequivalence or bioavailability studies for generics, reformulations, and bridging. Most studies enroll healthy volunteers, but oncology and some other indications use patient cohorts where dosing a healthy person is not appropriate.
Do Phase 1 / Early Clinical Unit studies have to be GCP compliant?
Yes. Everything at the clinical stage runs under Good Clinical Practice (ICH E6), and Phase 1 is no exception. The unit needs GCP-trained staff, validated systems, a clean trial master file, and documentation that an FDA or EMA inspector can read. Bioanalytical work supporting the PK data is expected to follow GLP or GCLP conventions with validated methods. When you screen units on BioBridgeX, GCP status and regulatory region are filterable, so you can confirm the standards your program needs before you talk to anyone.
How long does a first-in-human Phase 1 study take?
Once dosing starts, a SAD/MAD program commonly reads out within months, much faster than later phases, because enrollment of a captive healthy-volunteer panel is the easy part. The variables are the number of dose cohorts, the length of each escalation step with its safety-review windows, and bioanalytical turnaround on PK samples, since a slow assay can hold up the decision to escalate. Build the timeline backward from the safety reviews and the PK readout, not just the bench work, and confirm the unit's booking queue so your start date is real.
Can a Phase 1 unit handle biologics, cell therapy, and other complex modalities?
Some can, many cannot, and this is the most important fit question to ask. A unit that is excellent at small-molecule healthy-volunteer studies may be a beginner at a monoclonal antibody, an ADC, or a CAR-T, where infusion reactions, immunogenicity, longer observation, and patient (not healthy-volunteer) dosing change the safety setup entirely. Ask directly how many first-in-human studies the team has run in your modality. BioBridgeX covers all modalities, so you can filter for units that have actually dosed your kind of molecule rather than forcing the program onto a generalist.
How does sourcing a Phase 1 / Early Clinical Unit through BioBridgeX work?
BioBridgeX is a neutral marketplace, not a CRO and not an agent for any unit. You give the scope (study type, modality, indication, healthy-volunteer or patient, region), get matched with qualified GCP-compliant units, and compare them side by side on capacity, experience, and transparent quotes. Sourcing is free for buyers; suppliers pay a flat 2 percent fee, so there is no incentive to steer you toward a pricier unit. When your early-phase work pulls in other suppliers, a central lab, bioanalytical, a data manager, you compare quotes and contract directly with each chosen supplier in one place.

Source Phase 1 / Early Clinical Unit with one contract

Compare transparent quotes from qualified Phase 1 / Early Clinical Unit CROs, then contract once. Free for buyers.

Compare quotes